Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-16T22:35:00.368Z Has data issue: false hasContentIssue false

Antibiotic use and financial impact of a comprehensive beta-lactam allergy management program

Published online by Cambridge University Press:  10 April 2025

Karan Raja*
Affiliation:
Pharmacy Department, Clara Maass Medical Center, Belleville, NJ, USARutgers, The State University of New Jersey, New Brunswick, NJ, USA
Lakhini Vyas
Affiliation:
Pharmacy Department, Clara Maass Medical Center, Belleville, NJ, USA
Susan Morrison
Affiliation:
Medicine Department, Clara Maass Medical Center, Belleville, NJ, USA
Donald Beggs
Affiliation:
Medicine Department, Clara Maass Medical Center, Belleville, NJ, USA
Mitesh Patel
Affiliation:
Pharmacy Department, Clara Maass Medical Center, Belleville, NJ, USA
Mona Philips
Affiliation:
Pharmacy Department, Clara Maass Medical Center, Belleville, NJ, USA
*
Corresponding author: Karan Raja; Email: karan.raja@rwjbh.org

Abstract

Objective:

A multidisciplinary beta-lactam allergy management program was implemented at our community medical center to facilitate allergy documentation, conduct penicillin skin testing (PST), and decrease non-beta-lactam (NBL) use. This study measures PST-associated antibiotic use and financial outcomes.

Design:

Cohort study.

Setting:

Non-teaching, urban, community medical center within a multi-hospital health system.

Patients:

Adult inpatients who underwent PST and received antibiotic therapy during a 5-year period at our facility.

Methods:

Demographics, allergies, laboratory results, PST outcome, and antimicrobial regimens were assessed. Actual NBL days of therapy (DOT) were collected from the electronic medical record. NBL DOT that patients would have received without PST were modeled by forecasting the original regimen to end of inpatient treatment. Difference between actual and forecasted DOT was deemed DOT avoided (DOT-A) for each consecutively enrolled patient. The financial analysis evaluated cumulative NBL cost avoided. PST outcomes and average time from antibiotic initiation to PST were assessed.

Results:

The study included 600 patients who underwent PST an average of 3.7 days into treatment. The most common indication was acute bacterial skin and skin structure infections (23.9%). PST results were negative in 98% of patients. NBL DOT-A was 944.8/1000DT (8.8 DOT-A per intervention) accounting for an estimated cost savings of $206,500 ($344.10 per intervention), driven primarily by aztreonam avoidance.

Conclusions:

This study highlights significant avoidance of NBL DOT in one of the largest identified cohort of inpatients undergoing PST. Associated cost avoidance contributes to the sustainability and longevity of the allergy management program.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Figure 1.Patient CONSORT diagram.

Figure 1

Table 1.Baseline characteristics

Figure 2

Figure 2.Non-beta-lactam days of therapy per 1000 days of antibiotic therapy. Abbreviations: NBL, non-beta-lactam; DOT, days of therapy.

Figure 3

Table 2.Cost of NBL therapy

Figure 4

Table 3.Non-beta-lactam cost avoided